Patents Assigned to Mablife
  • Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
    Patent number: 10208124
    Abstract: The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 19, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), MABLIFE
    Inventors: Philippe Le Bouteiller, Armand Bensussan
  • Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
    Patent number: 9045544
    Abstract: The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM 1-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
    Type: Grant
    Filed: May 27, 2011
    Date of Patent: June 2, 2015
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), MABLIFE
    Inventors: Philippe Le Bouteiller, Armand Bensussan
  • ANTI-CD160 SPECIFIC ANTIBODIES FOR THE TREATMENT OF EYE DISORDERS BASED ON NEOANGIOGENESIS
    Publication number: 20130122006
    Abstract: The present invention relates to the use of at least one anti-CD 160 antibody, preferably a compound selected from CL1-R2 monoclonal antibody (which may be obtained by the hybridoma CNCM I-3204), its conservative fragments and its conservative derivatives, for preparing a drug designed to treat neovascular eye diseases.
    Type: Application
    Filed: May 27, 2011
    Publication date: May 16, 2013
    Applicants: Mablife, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Philippe Le Bouteiller, Armand Bensussan
  • Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
    Patent number: 8409573
    Abstract: The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: April 2, 2013
    Assignees: Mablife, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Laurence Boumsell, Jean Kadouche, Armand Bensussan